|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
7/13/2012 7:41:12 AM
Last night, Merck issued some surprising news about an experimental drug being developed to treat osteoperosis. A Phase III trial was ended early after the study of more than 16,000 patients, which began in 2007, met its primary efficacy outcomes, although the Data Monitoring Committee noted that safety issues remain in certain selected areas and a previously planned blinded extension trial will be needed to sort these out. The complete results will not be known for awhile, but the news was greeted as a pleasant surprise by investors, who have been cautious about the Merck pipeline and drove its stock up more than 4 percent by midday today. The new drug, called odanacatib, could become a much-needed successor to Fosamax, another osteoperosis drug in the bisophosponate class that generated $3 billion in annual sales before its patent expired four years ago.
|
|
|
|
|
|
|
|
|
|
|